Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,830,325
  • Shares Outstanding, K 43,210
  • Annual Sales, $ 1,599 M
  • Annual Income, $ 713,700 K
  • 36-Month Beta 1.26
  • Price/Sales 3.65
  • Price/Cash Flow 7.75
  • Price/Book 2.84

Price Performance

See More
Period Period Low Period High Performance
1-Month
122.25 +10.37%
on 02/09/18
143.73 -6.12%
on 01/23/18
-0.19 (-0.14%)
since 01/16/18
3-Month
119.92 +12.52%
on 11/27/17
152.55 -11.55%
on 01/03/18
+13.31 (+10.94%)
since 11/16/17
52-Week
112.01 +20.46%
on 04/26/17
169.89 -20.58%
on 02/21/17
-33.49 (-19.88%)
since 02/16/17

Most Recent Stories

More News
United Therapeutics Announces Settlement Of Patent Litigation With Actavis Laboratories FL, Inc. Relating To Orenitram

United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has entered into a Settlement Agreement with Actavis Laboratories FL, Inc. ("Actavis") resolving ongoing litigation concerning certain...

UTHR : 134.93 (-0.87%)
Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration

Celularity has been created through the contribution and acquisition of extensive intellectual property, clinical-stage assets, basic and clinical research, and product development expertise including:...

SRNE : 8.75 (-3.31%)
CELG : 95.26 (-0.92%)
UTHR : 134.93 (-0.87%)
Seattle Genetics is Among the Companies in the Biotechnology Industry with the Best Relative Performance (SGEN, UTHR, LJPC, VNDA, NLNK)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

LJPC : 33.87 (+2.76%)
SGEN : 54.48 (-0.67%)
VNDA : 17.10 (+1.18%)
UTHR : 134.93 (-0.87%)
NLNK : 7.11 (+3.95%)
Factors of Influence in 2018, Key Indicators and Opportunity within United Therapeutics, LTC Properties, WageWorks, Clearwater Paper, United Insurance, and CONMED -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of United Therapeutics Corporation...

WAGE : 57.00 (+0.62%)
UIHC : 18.79 (+0.43%)
LTC : 38.18 (+1.09%)
CNMD : 61.27 (+0.08%)
UTHR : 134.93 (-0.87%)
CLW : 37.05 (-2.11%)
Faruqi & Faruqi, LLP is Investigating United Therapeutics Corporation (UTHR) on Behalf of its Shareholders

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential wrongdoing at United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ: UTHR).

UTHR : 134.93 (-0.87%)
Spyryx Biosciences Expands with Election of Roger Jeffs, PhD as Independent Director

Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for severe pulmonary diseases, announced today the election of Dr. Roger Jeffs as a member of the Company's...

UTHR : 134.93 (-0.87%)
United Therapeutics (UTHR) Collaborates With Corsair Pharma

United Therapeutics (UTHR) entered into an exclusive license agreement with Corsair Pharma.

XOMA : 25.90 (-2.56%)
SCMP : 18.05 (+0.28%)
EXEL : 29.18 (-2.01%)
UTHR : 134.93 (-0.87%)
Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer

Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.

SGMO : 23.30 (+1.30%)
LGND : 157.14 (-0.03%)
ONCE : 54.50 (-0.89%)
GWPH : 131.01 (+0.26%)
SGEN : 54.48 (-0.67%)
UTHR : 134.93 (-0.87%)
BIIB : 291.87 (-2.51%)
Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs

United Therapeutics Corporation (NASDAQ: UTHR), a leading biotechnology company focused on development of therapies for the treatment of pulmonary arterial hypertension (PAH), and Corsair Pharma, Inc.,...

UTHR : 134.93 (-0.87%)
United Therapeutics Corporation To Present At 36th Annual J.P. Morgan Healthcare Conference

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's...

JPM : 114.68 (-0.72%)
UTHR : 134.93 (-0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability....

See More

Key Turning Points

2nd Resistance Point 140.76
1st Resistance Point 137.84
Last Price 134.93
1st Support Level 133.39
2nd Support Level 131.86

See More

52-Week High 169.89
Fibonacci 61.8% 147.78
Fibonacci 50% 140.95
Last Price 134.93
Fibonacci 38.2% 134.12
52-Week Low 112.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.